ClinicalTrials.gg
Active, not recruitingNCT05607550Updated Nov 2, 2026

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

A Phase 3 interventional study of furmonertinib 240 mg oral, daily and furmonertinib 160 mg oral, daily in Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer and EGFR Exon 20 Mutations, sponsored by ArriVent BioPharma, Inc.. Active, not recruiting at 208 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by ArriVent BioPharma, Inc. · Phase 3, Interventional, and Treatment

Updated Nov 2, 2026Primary completion moved32 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
398
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung — 31 open to participants now, 34 under way, 5 of them phase 3. aflutinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
4th of 41
398 · median 60
Started
2023
with 2 others
Phase 3
5 of 41
3 open now
Primary completion
2026-10
later than 13 of 33 live
Registered
14th of 41
by date
Lead sponsor
3 of 41
ArriVent BioPharma, Inc.

Among the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is one of 3 that started in 2023, is one of 5 in phase 3, reaches primary completion later than 13 of the 33 other live ones, and was the 14th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

31 of the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About aflutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily [QD] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib 160 mg QD, or platinum-based chemotherapy.

03

Conditions studied

  • Metastatic Non-Small Cell Lung Cancer
  • Advanced Non-Small Cell Lung Cancer
  • EGFR Exon 20 Mutations

Keywords

  • Non-Small Cell Lung Cancer (NSCLC)
  • Exon 20
  • Furmonertinib
  • Firmonertinib
  • AST2818
  • FURMO-004
  • Drug-Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • or cytologically documented, locally advanced or non-squamous Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy.
  • Documented results of the presence of an Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutation in tumor tissue or blood from local or central testing.
  • No prior systemic anticancer therapy regimens received for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) including prior treatment with any Epidermal Growth Factor Receptor (EGFR)-targeting agents (e.g., previous (EGFR) TKIs, monoclonal antibodies, or bispecific antibodies).
  • Patients who have received prior and/or adjuvant chemotherapy, immunotherapy, or chemo radiotherapy for non-metastatic disease (excluding EGFR-TKIs) must have experienced a treatment free interval of at least 12 months.
  • Patients with a history of treated or new asymptomatic CNS metastases are eligible.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
398 participants (actual)

Study arms

  • Experimental
    furmonertinib 240 mg

    Drug: furmonertinib 240 mg oral, daily

  • Experimental
    furmonertinib 160 mg

    Drug: furmonertinib 160 mg oral, daily

  • Active comparator
    platinum-based chemotherapy

    carboplatin or cisplatin based on investigator's choice + pemetrexed intravenously

    Drug: platinum-based chemotherapy

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) determined by blinded independent central review (BICR)

    Time frame: Up to 32 months after first dose

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to 62 months after first dose

  2. PFS determined by investigator assessment

    Time frame: Up to 36 months after first dose

  3. Overall response rate (ORR)

    Time frame: Up to 36 months after first dose

  4. Duration of response (DOR)

    Time frame: Up to 36 months after first dose

  5. Time to second Progression Free Survival (PFS2)

    Time frame: Up to 36 months after first dose

  6. PFS by blinded independent central review (BICR) in patients with a history or presence of brain metastases at baseline

    Time frame: Up to 36 months after first dose

  7. Time to central nervous system (CNS) metastases by BICR

    Time frame: Randomization up to ≤30 days after last dose

  8. CNS ORR evaluated by BICR

    Time frame: Randomization up to ≤30 days after last dose

  9. CNS DOR evaluated by BICR

    Time frame: Randomization up to ≤30 days after last dose

  10. CNS PFS evaluated by BICR

    Time frame: Randomization up to ≤30 days after last dose

  11. Change in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30)

    QLQ-C30 is a cancer-specific questionnaire comprised of 5 functional scales (physical, role, cognitive, emotional, and social functioning); 3 symptom scales (fatigue, pain, and nausea/vomiting); and a global health status/quality-of-life (QoL) scale. Six single-item scales are also included (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).

    Time frame: Randomization up to ≤30 days after last dose

  12. Change in EORTC QLQ Lung Cancer Module Core 13 (QLQ LC13)

    QLQ-LC13 is a cancer-specific questionnaire which comprises of 13 questions assessing lung cancer-associated symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and use of pain medication.

    Time frame: Randomization up to ≤30 days after last dose

  13. Change in Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC SAQ)

    NSCLC-SAQ consists of 7 items assessing 5 NSCLC symptom concepts: cough, pain, dyspnea, fatigue, and poor appetite.

    Time frame: Randomization up to ≤30 days after last dose

  14. Number of incidence and severity of adverse events (AEs) as a measure of safety and tolerability of Furmonertinib

    Time frame: Up to 36 months after first dose

  15. Plasma concentrations of furmonertinib and its major metabolite (AST5902)

    Time frame: Up to 36 months after first dose

07

Study locations

208 sites
  • Arrivent Investigative Site
    Daphne, Alabama 36526, United States
  • Arrivent Investigative Site
    Yuma, Arizona 85364, United States
  • Arrivent Investigative Site
    Fayetteville, Arkansas 72703, United States
  • Arrivent Investigative Site
    Beverly Hills, California 90212, United States
  • Arrivent Investigative Site
    Fullerton, California 92835, United States
  • Arrivent Investigative Site
    Long Beach, California 90806, United States
  • Arrivent Investigative Site
    Los Alamitos, California 90720, United States
  • Arrivent Investigative Site
    Napa, California 94558, United States
  • Arrivent Investigative Site
    Orange, California 90868, United States
  • Arrivent Investigative Site
    Orange, California 92868, United States
  • Arrivent Investigative site
    Sacramento, California 95817, United States
  • Arrivent Investigative Site
    San Diego, California 92123, United States
  • Arrivent Investigative Site
    Santa Barbara, California 93105, United States
  • Arrivent Investigative Site
    Santa Monica, California 90404, United States
  • Arrivent Investigative Site
    Santa Rosa, California 95403, United States
  • Arrivent Investigative Site
    Whittier, California 90602, United States
  • Arrivent Investigative Site
    Hartford, Connecticut 06102, United States
  • Arrivent Investigative Site
    Norwich, Connecticut 06360, United States
  • Arrivent Investigative Site
    Fort Myers, Florida 33901, United States
  • Arrivent Investigative Site
    St. Petersburg, Florida 33705, United States
  • Arrivent Investigative Site
    The Villages, Florida 32159, United States
  • Arrivent Investigative Site
    Peoria, Illinois 61615, United States
  • Arrivent Investigative Site
    Rolling Meadows, Illinois 60008, United States
  • Arrivent Investigative Site
    Fort Wayne, Indiana 46804, United States
  • Arrivent Investigative Site
    Indianapolis, Indiana 46250, United States
  • Arrivent Investigative Site
    South Bend, Indiana 46601, United States
  • Arrivent Investigative Site
    Bethesda, Maryland 20817, United States
  • Arrivent Investigative Site
    Frederick, Maryland 21702, United States
  • Arrivent Investigative Site
    Rockville, Maryland 20850, United States
  • Arrivent Investigative Site
    Fairhaven, Massachusetts 02719, United States
  • Arrivent Investigative Site
    Lansing, Michigan 48912, United States
  • Arrivent Investigative Site
    Bolivar, Missouri 65613, United States
  • Arrivent Investigative Site
    Kansas City, Missouri 64111, United States
  • Arrivent Investigative Site
    Saint Joseph, Missouri 64507, United States
  • Arrivent Investigative Site
    St Louis, Missouri 63110, United States
  • Arrivent Investigative Site
    Omaha, Nebraska 68114, United States
  • Arrivent Investigative Site
    Belleville, New Jersey 07109, United States
  • Arrivent Investigative Site
    Englewood, New Jersey 07631, United States
  • Arrivent Investigative Site
    Florham Park, New Jersey 07932, United States
  • Arrivent Investigative Site
    The Bronx, New York 10461, United States
  • Arrivent Investigative Site
    Goldsboro, North Carolina 27534, United States
  • ArriVent Investigative Site
    Pinehurst, North Carolina 28374, United States
  • Arrivent Investigative Site
    Canton, Ohio 44708, United States
  • Arrivent Investigative Site
    Cincinnati, Ohio 45220, United States
  • ArriVent Investigative Site
    Cincinnati, Ohio 45242, United States
  • Arrivent Investigative Site
    Cleveland, Ohio 44195, United States
  • Arrivent Investigative Site
    Columbus, Ohio 43214, United States
  • Arrivent Investigative Site
    Oklahoma City, Oklahoma 73102, United States
  • Arrivent Investigative Site
    Tulsa, Oklahoma 74146, United States
  • Arrivent Investigative Site
    Salem, Oregon 97301, United States
  • Arrivent Investigative Site
    Gettysburg, Pennsylvania 17325, United States
  • ArriVent Investigative Site
    Langhorne, Pennsylvania 19047, United States
  • Arrivent Investigative Site
    York, Pennsylvania 17403, United States
  • Arrivent Investigative Site
    Greenville, South Carolina 29607, United States
  • Arrivent Investigative Site
    Sioux Falls, South Dakota 57117, United States
  • Arrivent Investigative Site
    Memphis, Tennessee 38120, United States
  • ArriVent Investigative Site
    Nashville, Tennessee 37203, United States
  • Arrivent Investigative Site
    Abilene, Texas 79606, United States
  • ArriVent Investigative Site
    Austin, Texas 78745, United States
  • Arrivent Investigative Site
    Houston, Texas 77030, United States
  • Arrivent Investigative Site
    Plano, Texas 75093, United States
  • Arrivent Investigative Site
    Ogden, Utah 84405, United States
  • Arrivent Investigative Site
    Salt Lake City, Utah 84106, United States
  • ArriVent Investigative Site
    Fairfax, Virginia 22031, United States
  • Arrivent Investigative Site
    Fredericksburg, Virginia 22408, United States
  • Arrivent Investigative Site
    Bellingham, Washington 98225, United States
  • Arrivent Investigative Site
    Spokane Valley, Washington 99216, United States
  • Arrivent Investigative Site
    Tacoma, Washington 98405, United States
  • Arrivent Investigative Site
    Appleton, Wisconsin 54911, United States
  • ArriVent Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Arrivent Investigative Site
    Blacktown, 2148, Australia
  • Arrivent Investigative Site
    St Leonards, NSW 2065, Australia
  • Arrivent Investigative Site
    Woolloongabba, 4102, Australia
  • ArriVent Investigative Site
    Salvador, Estado de Bahia 40170-110, Brazil
  • ArriVent Investigative Site
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • ArriVent Investigative Site
    Porto Alegre, Porto Alegre 91350-200, Brazil
  • ArriVent Investigative Site
    Rio de Janeiro, Rio de Janeiro 20231-050, Brazil
  • ArriVent Investigative Site
    Rio de Janeiro, Rio de Janeiro 22281-100, Brazil
  • ArriVent Investigative Site
    Pelotas, Rio Grande do Sul 96020-080, Brazil
  • ArriVent Investigative Site
    Porto Alegre, Rio Grande 90035-903, Brazil
  • ArriVent Investigative Site
    Blumenau, SC Cep 89015-200, Brazil
  • ArriVent Investigative Site
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • ArriVent Investigative Site
    São Paulo, São Paulo 01321-001, Brazil
  • ArriVent Investigative Site
    Liberdade, São Paulo/SP 01509-010, Brazil
  • ArriVent Investigative Site
    Taubaté, Taubate SP 12030-200, Brazil
  • ArriVent Investigative Site
    Edmonton, Alberta T6G 1Z2, Canada
  • ArriVent Investigative Site
    Toronto, Ontario M5G 1Z5, Canada
  • Allist Investigative Site
    Beijing, Beijing Municipality 101149, China
  • Allist Investigative Site
    Meizhou, Guangdong 514000, China
  • Allist Investigative Site
    Xuhui, Hai City 200030, China
  • Allist Investigative Site
    Hangzhou, Hangzhou 310018, China
  • Allist Investigative Site
    Cangzhou, Hebei 061011, China
  • Allist Investigative Site
    Shushan, Hefei 230022, China
  • Allist Investigative Site
    Zhengzhou, Henan 450052, China
  • Allist Investigative Site
    Changchun, Jilin 130000, China
  • Allist Investigative Site
    Weihai, Lingang Economic and Technological Development Zo 264200, China
  • Allist Investigative Site
    Nanning, Nanning 530000, China
  • Allist Investigative Site
    Yangpu, Shanghai Municipality 201321, China
  • Allist Investigative Site
    Xi’an, Shanxi 710061, China
  • Allist Investigative Site
    Taiyuan, Taiyuan 030013, China

Showing the first 100 of 208 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Oct 2026, 40 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 40 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2025 → Oct 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2022
First posted
Nov 7, 2022
StartActual
Jun 1, 2023
Primary completionActual
Oct 6, 2026was Aug 2025
CompletionEst.
Feb 15, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
32 sites added, 32 sites removed
Show 32 added (7 Brazil, 5 China, 4 Taiwan, 3 United States, 3 United Kingdom, 2 Israel, 2 Italy, 2 Japan, 1 Mexico, 1 Philippines, 1 Singapore, 1 Spain)
  • Arrivent Investigative Site · St. Petersburg, United States
  • Arrivent Investigative Site · St Louis, United States
  • Arrivent Investigative Site · The Bronx, United States
  • ArriVent Investigative Site · Salvador, Brazil
  • ArriVent Investigative Site · Porto Alegre, Brazil
  • ArriVent Investigative Site · Rio de Janeiro, Brazil
  • ArriVent Investigative Site · Rio de Janeiro, Brazil
  • ArriVent Investigative Site · Pelotas, Brazil
  • ArriVent Investigative Site · São José do Rio Preto, Brazil
  • ArriVent Investigative Site · São Paulo, Brazil
  • Allist Investigative Site · Beijing, China
  • Allist Investigative Site · Meizhou, China
  • Allist Investigative Site · Weihai, China
  • Allist Investigative Site · Yangpu, China
  • Allist Investigative Site · Xi’an, China
  • ArriVent Investigative Site · Beersheba, Israel
  • ArriVent Investigative Site · Haifa, Israel
  • ArriVent Investigative Site · Bari, Italy
  • ArriVent Investigative Site · Milan, Italy
  • ArriVent Investigative Site · Tokyo, Japan
  • Arrivent Investigative Site · Sapporo, Japan
  • ArriVent Investigative Site · Mexico City, Mexico
  • ArriVent Investigative Site · Manila, Philippines
  • ArriVent Investigative Site · Singapore, Singapore
  • ArriVent Investigative Site · Madrid, Spain
  • ArriVent Investigative Site · Kaohsiung City, Taiwan
  • ArriVent Investigative Site · Taichung, Taiwan
  • Arrivent Investigative Site · Chang-hua, Taiwan
  • Arrivent Investigative Site · Kaohsiung City, Taiwan
  • ArriVent Investigative Site · London, United Kingdom
  • …and 2 more on the registry record
Show 32 removed
  • Arrivent Investigative Site · Saint Petersburg, United States
  • Arrivent Investigative Site · Saint Louis, United States
  • Arrivent Investigative Site · Bronx, United States
  • ArriVent Investigative Site · Salvador, Brazil
  • ArriVent Investigative Site · Rio De Janeiro, Brazil
  • ArriVent Investigative Site · Rio De Janeiro, Brazil
  • ArriVent Investigative Site · Pelotas, Brazil
  • ArriVent Investigative Site · São José Do Rio Preto, Brazil
  • ArriVent Investigative Site · São Paulo, Brazil
  • ArriVent Investigative Site · Porto Alegre, Brazil
  • Allist Investigative Site · Beijing, China
  • Allist Investigative Site · Meizhou City, China
  • Allist Investigative Site · Weihai, China
  • Allist Investigative Site · Yangpu, China
  • Allist Investigative Site · Xi'an, China
  • ArriVent Investigative Site · Be'er Sheva, Israel
  • ArriVent Investigative Site · Haifa, Israel
  • ArriVent Investigative Site · Bari, Italy
  • ArriVent Investigative Site · Milano, Italy
  • Arrivent Investigative Site · Sapporo-shi, Japan
  • ArriVent Investigative Site · Tokyo, Japan
  • ArriVent Investigative Site · Ciudad de mexico, Mexico
  • ArriVent Investigative Site · Manila, Philippines
  • ArriVent Investigative Site · Singapore, Singapore
  • ArriVent Investigative Site · Madrid, Spain
  • Arrivent Investigative Site · Chang Hua, Taiwan
  • Arrivent Investigative Site · Kaohsiung, Taiwan
  • ArriVent Investigative Site · Kaohsiung, Taiwan
  • ArriVent Investigative Site · Taichung, Taiwan
  • ArriVent Investigative Site · London, United Kingdom
  • …and 2 more on the registry record
Nov 2, 2026
Primary completion
Aug 15, 2025→Oct 6, 2026 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    32 sites added, 32 sites removed
    Show 32 added (7 Brazil, 5 China, 4 Taiwan, 3 United States, 3 United Kingdom, 2 Israel, 2 Italy, 2 Japan, 1 Mexico, 1 Philippines, 1 Singapore, 1 Spain)
    • Arrivent Investigative Site · St. Petersburg, United States
    • Arrivent Investigative Site · St Louis, United States
    • Arrivent Investigative Site · The Bronx, United States
    • ArriVent Investigative Site · Salvador, Brazil
    • ArriVent Investigative Site · Porto Alegre, Brazil
    • ArriVent Investigative Site · Rio de Janeiro, Brazil
    • ArriVent Investigative Site · Rio de Janeiro, Brazil
    • ArriVent Investigative Site · Pelotas, Brazil
    • ArriVent Investigative Site · São José do Rio Preto, Brazil
    • ArriVent Investigative Site · São Paulo, Brazil
    • Allist Investigative Site · Beijing, China
    • Allist Investigative Site · Meizhou, China
    • Allist Investigative Site · Weihai, China
    • Allist Investigative Site · Yangpu, China
    • Allist Investigative Site · Xi’an, China
    • ArriVent Investigative Site · Beersheba, Israel
    • ArriVent Investigative Site · Haifa, Israel
    • ArriVent Investigative Site · Bari, Italy
    • ArriVent Investigative Site · Milan, Italy
    • ArriVent Investigative Site · Tokyo, Japan
    • Arrivent Investigative Site · Sapporo, Japan
    • ArriVent Investigative Site · Mexico City, Mexico
    • ArriVent Investigative Site · Manila, Philippines
    • ArriVent Investigative Site · Singapore, Singapore
    • ArriVent Investigative Site · Madrid, Spain
    • ArriVent Investigative Site · Kaohsiung City, Taiwan
    • ArriVent Investigative Site · Taichung, Taiwan
    • Arrivent Investigative Site · Chang-hua, Taiwan
    • Arrivent Investigative Site · Kaohsiung City, Taiwan
    • ArriVent Investigative Site · London, United Kingdom
    • …and 2 more on the registry record
    Show 32 removed
    • Arrivent Investigative Site · Saint Petersburg, United States
    • Arrivent Investigative Site · Saint Louis, United States
    • Arrivent Investigative Site · Bronx, United States
    • ArriVent Investigative Site · Salvador, Brazil
    • ArriVent Investigative Site · Rio De Janeiro, Brazil
    • ArriVent Investigative Site · Rio De Janeiro, Brazil
    • ArriVent Investigative Site · Pelotas, Brazil
    • ArriVent Investigative Site · São José Do Rio Preto, Brazil
    • ArriVent Investigative Site · São Paulo, Brazil
    • ArriVent Investigative Site · Porto Alegre, Brazil
    • Allist Investigative Site · Beijing, China
    • Allist Investigative Site · Meizhou City, China
    • Allist Investigative Site · Weihai, China
    • Allist Investigative Site · Yangpu, China
    • Allist Investigative Site · Xi'an, China
    • ArriVent Investigative Site · Be'er Sheva, Israel
    • ArriVent Investigative Site · Haifa, Israel
    • ArriVent Investigative Site · Bari, Italy
    • ArriVent Investigative Site · Milano, Italy
    • Arrivent Investigative Site · Sapporo-shi, Japan
    • ArriVent Investigative Site · Tokyo, Japan
    • ArriVent Investigative Site · Ciudad de mexico, Mexico
    • ArriVent Investigative Site · Manila, Philippines
    • ArriVent Investigative Site · Singapore, Singapore
    • ArriVent Investigative Site · Madrid, Spain
    • Arrivent Investigative Site · Chang Hua, Taiwan
    • Arrivent Investigative Site · Kaohsiung, Taiwan
    • ArriVent Investigative Site · Kaohsiung, Taiwan
    • ArriVent Investigative Site · Taichung, Taiwan
    • ArriVent Investigative Site · London, United Kingdom
    • …and 2 more on the registry record
    Primary completion Aug 15, 2025→Oct 6, 2026 (now actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05607550
Lead sponsor
ArriVent BioPharma, Inc.
Responsible party
Sponsor
First posted
Nov 7, 2022
Start date
Jun 1, 2023
Primary completion
Oct 6, 2026
Completion
Feb 15, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Jamuna Thimmarayappa
study director · ArriVent BioPharm

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflutinib

Start the discussion